Literature DB >> 8026983

HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products.

N Tanigaki1, D Fruci, A Chersi, G Falasca, R Tosi, R H Butler.   

Abstract

Seven A2-binding peptides were tested by the HLA class I alpha-chain refolding assay previously described for their direct binding to HLA class I alpha chains derived from a panel of 18 HLA-homozygous B-cell lines of various HLA specificities, including four A2 subtypes: A*0201, A*0204, A*0205, and A*0206. All but one test peptide possessed the major anchor residue motifs, L-V, L-L, or I-L, of A2(A*0201)/A2(A*0205)-binding peptides or the closely related motifs, I-V or V-V. This cell panel analysis confirmed the high A2 allele specificity of the test peptides, but also revealed the existence of a broad cross-binding within the A2 subgroup. Most peptides bound to the alpha chains of the A2 subtypes tested, although their binding patterns showed differences. Furthermore, the A2-binding peptides carrying the I-V or V-V motif were found to cross-react also outside of the A2 subtypes, probably with A24, A26, A28, and A29. Other A-locus allelic products, A1, A3, A11, A30, and A31, and the B-locus allelic products carried by the cells tested were essentially negative, although a few exceptions were seen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8026983     DOI: 10.1016/0198-8859(94)90255-0

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  7 in total

1.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

Review 2.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

3.  Vigorous but short-term gamma interferon T-cell responses against a dominant HLA-A*02-restricted measles virus epitope in patients with measles.

Authors:  Assan Jaye; Carla A Herberts; Sabelle Jallow; Sowsan Atabani; Michel R Klein; Peter Hoogerhout; Michael Kidd; Cécile A C M van Els; Hilton C Whittle
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  The role of HLA class I gene variation in autoimmune diabetes.

Authors:  Charles Sia; Michael Weinem
Journal:  Rev Diabet Stud       Date:  2005-08-10

5.  HLA-A2 subtypes are functionally distinct in peptide binding and presentation.

Authors:  D Barouch; T Friede; S Stevanović; L Tussey; K Smith; S Rowland-Jones; V Braud; A McMichael; H G Rammensee
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

6.  A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes.

Authors:  S Shichijo; M Nakao; Y Imai; H Takasu; M Kawamoto; F Niiya; D Yang; Y Toh; H Yamana; K Itoh
Journal:  J Exp Med       Date:  1998-02-02       Impact factor: 14.307

7.  Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes.

Authors:  P Panina-Bordignon; R Lang; P M van Endert; E Benazzi; A M Felix; R M Pastore; G A Spinas; F Sinigaglia
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.